• David M Simpson, Jessica Robinson-Papp, Joanna Van, Malcolm Stoker, Hélène Jacobs, Robert J Snijder, Diederik S Schregardus, Stephen K Long, Bruno Lambourg, and Nathaniel Katz.
• Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: david.simpson@mssm.edu.
• J Pain. 2017 Jan 1; 18 (1): 42-53.

AbstractThis 12-week study evaluated the efficacy and safety of capsaicin 8% patch versus placebo patch in painful diabetic peripheral neuropathy (PDPN). Patients aged 18 years or older with PDPN were randomized (1:1) to one 30-minute treatment (capsaicin 8% patch or placebo patch) to painful areas of the feet. Overall, 369 patients were randomized (capsaicin 8% patch, n = 186; placebo patch, n = 183). Percentage reduction in average daily pain score from baseline to between weeks 2 through 8 (the primary end point) was statistically significant for capsaicin 8% patch versus placebo (-27.4% vs -20.9%; P = .025); improvements in pain were observed from week 2 onward. Versus placebo, patients treated with capsaicin 8% patch had a shorter median time to treatment response (19 vs 72 days) and modest improvements in sleep interference scores from baseline to between weeks 2 through 8 (P = .030) and weeks 2 through 12 (P = .020). Apart from application site reactions, treatment-emergent adverse events were similar between groups. No indications of deterioration in sensory perception of sharp, cold, warm, or vibration stimuli were observed. In patients with PDPN, capsaicin 8% patch treatment provided modest pain relief and sleep quality improvements versus a placebo patch, similar in magnitude to other treatments with known efficacy, but without systemic side effects or sensory deterioration.Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

27 keywords...

hide…